Medical/Pharmaceuticals
GMP cell CDMO I Peace, Inc. in collaboration with universities successfully converted human dermal fibroblasts into oligodendrocyte by direct reprogramming
PALO ALTO, Calif., Sept. 20, 2022 /PRNewswire/ -- Koji Tanabe of I Peace, Inc. (
https://www.ipeace.com
2022-09-21 05:39
1904
Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy
Regulatory Authorization Granted to Proceed with ATH434 Phase 2 Clinical Trial MELBOURNE, Australia and SAN FRANCISCO, Sept. 20, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying tr...
2022-09-20 19:25
2432
Special interview with Dr. Patrick Yu-Wai-Man on International LHON Awareness Day
WUHAN, China and SAN DIEGO, Sept. 19, 2022 /PRNewswire/ -- September 19th is International LHON Awareness Day. LHON is a debilitating disease that leads to quick vision loss concomitantly or successively. It mostly impacts young adolescent males and brings tremendous physical and psychological st...
2022-09-19 20:00
3040
New treatment for rare cancer cholangiocarcinoma approved in Australia
* Available to treat adults with locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement * PEMAZYRE® (pemigatinib) is available via a co-pay access program in Australia SINGAPORE, Sept. 15, 2022 /PRNewswire/ -- A NEW targeted therapy to treat a rare bile duct c...
2022-09-15 21:00
2269
Hexvix®, A Diagnostic Drug of Asieris, is Now Covered by the 2022 Lecheng Global Specialty Drug Insurance
SHANGHAI, Sept. 15, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced today that Hexvix®, a drug used for...
2022-09-15 17:07
2121
J INTS BIO, poster presentation of further preclinical data of its Novel Oral 4th Generation EGFR-TKI 'JIN-A02' at the 2022 European Society for Medical Oncology Congress in Paris, France (ESMO 2022)
SEOUL, South Korea, Sept. 15, 2022 /PRNewswire/ -- J INTS BIO announced the poster presentation of its novel, orally administered 4th generation EGFR-TKI 'JIN-A02' at the 2022 edition of the European Society for Medical Oncology Congress (ESMO 2022) held inParis, France from 9th to 13th September...
2022-09-15 14:12
1721
United Imaging Announces Clinical System Installations at Huntsman Cancer Institute at the University of Utah
Agreement envisions expansion of cutting-edge clinical services.
HOUSTON, Sept. 14, 2022 /PRNewswire/ -- United Imaging, a global leader in
advanced medical imaging and radiotherapy equipment, announced that TheCenter
for Quantitative Cancer Imaging
2022-09-14 21:00
1903
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Sept. 14, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment ...
2022-09-14 20:30
3342
DR CATHERINE MOHR TO JOIN BOARD OF MEDTECH COMPANY AROA BIOSURGERY
AUCKLAND, New Zealand, Sept. 14, 2022 /PRNewswire/ -- New Zealand based soft
tissue regeneration company Aroa Biosurgery (AROA) is delighted to announce the
appointment of award-winning medical researcher and inventor, Dr.Catherine Mohr
as a Non-Executive Director to the board.
2022-09-14 13:05
3373
MD ANDERSON AND RADIOPHARM THERANOSTICS LAUNCH JOINT VENTURE TO DEVELOP NOVEL RADIOPHARMACEUTICALS
MELBOURNE, Australia, Sept. 13, 2022 /PRNewswire/ -- The University of Texas MD
Anderson Cancer Center
2022-09-14 11:09
1930
New Study by Lunit and MGH Validates Effectiveness of AI as Aid in Chest X-Ray Interpretation - Published in JAMA Network Open
* Joint study with Massachusetts General Hospital proves that Lunit's
AI-powered chest x-ray analysis software enhances the overall performance and
efficiency of radiologists SEOUL, South Korea, Sept. 13, 2022 /PRNewswire/ -- A
recent study published in
2022-09-13 22:16
2128
EDGC (Eone Diagnomics Genome Center) recruits Sam Martin, Vice President of Overseas Business Development... to "accelerate entering the overseas market"
* An expert from Invitae and Ambry Genetics, U.S. genome analysis companies * EDGC states, "We will expand the overseas genome analysis market and advance into the global liquid biopsy technology market by recruiting a global talent in the genome field" * Worked in a non-profit research orga...
2022-09-13 21:00
2252
I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome
GAITHERSBURG, Md. and SHANGHAI, Sept, 13, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it has successfully completed an End-of-Phase 2 (...
2022-09-13 20:00
2797
First and only TIGIT/TGF-β dual-targeting antibody fusion protein of Akeso demonstrated promise in preclinical results published at ESMO
HONG KONG, Sept, 13, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso"), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, published encouraging preclinical results in poster featuring its F...
2022-09-13 14:02
1932
SeekIn Receives CE Mark Approval for OncoSeek® Multi-Cancer Detection Test
This Blood-based Multi-Cancer Early Detection Test Combines Protein Tumor Markers And Artificial Intelligence SHENZHEN, China, Sept. 12, 2022 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, today announced CE (Conformité Européenne) Mark appr...
2022-09-12 21:37
1896
I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022
* Lemzoparlimab combined with AZA showed encouraging clinical response in higher-risk MDS patients * For patients received initial dose over 3 months, the ORR is 80.6% and for patients received initial dose over 6 months the ORR is 86.7%, CR rate 40% * Lemzoparlimab does not require priming ...
2022-09-10 21:00
2695
Redbud raises $10M in series A round as CRO focusing on science-driven clinical development
SHANGHAI, Sept. 9, 2022 /PRNewswire/ -- Redbud Medicine, the Delaware -headquartered contract research organization (CRO) announced on Monday following the completion of a series A round fundraising in which MING Bioventures Capital, Delian Capital and the existing Angel round investor Hongfeng C...
2022-09-10 05:13
2419
WuXi STA Opens a New Sterile Lipid Nanoparticle Formulation Facility to Enhance Global CRDMO Services for Customers
SHANGHAI, Sept. 9, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new sterile lipid nanoparticle (LNP) formulation development and manufacturing facility at its Wuxi city campus. Created in response to the increasing demand for complex injection dosag...
2022-09-09 20:00
2901
111 Inc. Receives Unsolicited Preliminary Non-Binding Proposal to Acquire the Company
SHANGHAI, Sept. 9, 2022 /PRNewswire/ -- 111 Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company inChina, today announced that its Board of Directors (the "Board") has received an unsolicited preliminary non-binding proposal letter (the "Proposal") dated...
2022-09-09 17:53
2651
Antengene to Present at Upcoming Industry Conferences
SHANGHAI and HONG KONG, Sept. 9, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hem...
2022-09-09 14:43
2311
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 274 media titles]
2026-10-09 13:21The Coffee Bean & Tea Leaf® Turns 63 and Sets a New Direction for Its Next Chapter of Growth
[Picked up by 263 media titles]
2026-10-05 13:24
Most Read
RoboParty Unveils RP1, a High-Performance Full-Stack Open-Source Humanoid Robot at IROS
2026-10-04 00:56
10506
Nuix Neo Generative AI Framework
2026-10-08 08:02
9010
Silicon Quantum Computing Named to Fast Company's 2026 Next Big Things in Tech List
2026-10-06 19:38
7964
